Sigma Planning Corp’s Cymabay Therapeutics CBAY Stock Holding History

Sigma Planning Corp’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-30,700	Closed	-$399K	–	950
2018 Q1	$399K	Buy	30,700 +3,400	+12%	+$42.2K	0.03%	506
2017 Q4	$251K	Buy	27,300 +12,300	+82%	+$105K	0.02%	680
2017 Q3	$121K	Buy	15,000 +1,000	+7%	+$6.76K	0.01%	812
2017 Q2	$81K	Sell	14,000 -85	-0.6%	-$362	0.01%	765
2017 Q1	$61K	Buy	+14,085	New	+$40.4K	0.01%	758

Other funds holding CBAY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Sigma Planning Corp's CBAY Position: Q2 2018 in Review

Sigma Planning Corp sold out of Cymabay Therapeutics (CBAY) in Q2 2018, closing a stake of 30,700 shares — an estimated $399K sold.

Sigma Planning Corp first reported a position in CBAY in Q1 2017 and held it in 5 quarters. The position peaked at $399K in Q1 2018. 118 funds tracked by Wall St. Rank hold CBAY as of Q2 2018.

Sigma Planning Corp reported no remaining Cymabay Therapeutics position as of Q2 2018 after selling out during the quarter.
Sigma Planning Corp sold 30,700 Cymabay Therapeutics shares in Q2 2018, an estimated $399K.
Sigma Planning Corp first reported a position in Cymabay Therapeutics in Q1 2017 and held it in 5 quarters.
Sigma Planning Corp's Cymabay Therapeutics position peaked at $399K in Q1 2018.
118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2018.

Based on Sigma Planning Corp's 13F filing for Q2 2018, filed 2 Aug 2018.